Anixa BiosciencesNASDAQ: ANIX
Pipeline
NewsContactInvestors
Legal

Forward-Looking Statements

This notice applies to forward-looking statements made on anixa.com, on our investor relations website at ir.anixa.com, and in the Company's communications. Last updated June 2026.

1. Safe-harbor notice

This website, our investor relations website at ir.anixa.com, and the Company's other communications contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements are statements that are not historical facts and may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” “target,” “may,” “will,” “would,” “could,” “should,” “estimate,” “potential,” and similar expressions, or the negatives thereof.

2. Examples of forward-looking statements

Forward-looking statements on this website include, without limitation, statements regarding:

  • The Company's immuno-oncology strategy and the anticipated benefits of its CAR-T and cancer vaccine programs;
  • The timing, progress, design, enrollment, and results of preclinical studies and clinical trials, including the ovarian cancer CAR-T (lira-cel) and breast cancer vaccine programs;
  • Anticipated clinical and regulatory milestones, including the advancement of programs into and through later-stage trials;
  • The Company's collaborations with research and clinical institutions, including Cleveland Clinic, Moffitt Cancer Center, and others;
  • The potential therapeutic benefits, mechanisms, and market opportunities for the Company's product candidates; and
  • The Company's business strategy, intellectual property, and future research opportunities.

3. Risks and uncertainties

Forward-looking statements are based on management's current expectations and assumptions and are subject to known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or events to differ materially from those expressed or implied. These factors include, among others:

  • Anixa is a clinical-stage company with no approved products and a history of operating losses;
  • Preclinical and early clinical results are not necessarily predictive of future results, and results from early trials may not be replicated in later or larger trials;
  • The Company may be unable to advance its product candidates through clinical development on the anticipated timelines, or at all, and may not obtain or maintain required regulatory approvals;
  • Risks relating to the safety, efficacy, manufacturing, and supply of the Company's product candidates;
  • The Company depends on collaborators and third parties to conduct and support its programs, and the loss of any such relationship could harm its development efforts;
  • The Company will require substantial additional funding to advance its programs and may be unable to raise capital on acceptable terms, or at all;
  • Risks relating to intellectual property protection, competition, and the broader regulatory, legal, and commercial environment; and
  • The other risks and uncertainties described in the Company's filings with the SEC.

4. Clinical-stage status

Anixa's product candidates are investigational and are being evaluated in preclinical and clinical studies. None has been approved by the FDA or any other regulatory authority, and their safety and efficacy have not been established. References to potential indications, mechanisms, or benefits are investigational and do not constitute claims of safety or efficacy.

5. No duty to update

Forward-looking statements speak only as of the date on which they are made. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. You should not place undue reliance on any forward-looking statement.

6. No offer of securities

Nothing on this website constitutes an offer to sell, or a solicitation of an offer to buy, any security, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

7. Where to find more information

For a more complete discussion of the risks and uncertainties that could cause actual results to differ materially from those expressed or implied by forward-looking statements, please refer to the Company's filings with the SEC, including its periodic reports, which are available through the Company's investor relations site and at www.sec.gov.

Investor inquiries may be directed to info@anixa.com or 408-708-9808.